INTRODUCTION
The bleeding time is a measurement of platelet and capillary interaction following a small standardized cutaneous incision. 1 The duration of bleeding, in this test, roughly corresponds with the risk of ''platelet-type'' hemorrhage. 2 In adult humans, and in adult animal models, anemia causes a prolongation of the bleeding time. 3 -7 Increasing the hematocrit of anemic subjects by erythrocyte transfusion or recombinant erythropoietin administration normalizes the bleeding time. 3 -7 On this basis it has been suggested that anemia increases the risk of hemorrhage. 5 -7 The mechanism by which anemia prolongs the bleeding time is not known, but two hypotheses have been proposed. First, since platelets are nonmotile, they arrive at exposed vascular subendothelium by being pushed there by blood flow, largely by erythrocytes. Therefore, it has been proposed that platelets find exposed subendothelium in proportion to the hematocrit of the blood flowing by the incision. 7 A second hypothesis is that erythrocytes facilitate activation of platelets by releasing ADP following vessel injury, and that anemic individuals have less erythrocyte-derived ADP available for platelet activation. 7 Very low birth weight (VLBW) infants ( <1500 g birth weight) frequently develop anemia during their first week of life, as a consequence of beginning life with a lower hematocrit than they would have at term, 8 compounded by phlebotomy losses for laboratory tests. 8 -10 Fifteen to twenty years ago, it was commonly recommended that hematocrits of VLBW infants be maintained above 0.40 l/l, 9 but current recommendations sometimes permit hematocrits to fall to 0.25 l/l before a transfusion is administered. 10 However, if a low hematocrit significantly lengthens the bleeding time of VLBW neonates, perhaps permitting their hematocrits to fall to such levels increases their risk of hemorrhage.
We hypothesized that bleeding times of VLBW infants would be prolonged when their hematocrits were low and would shorten following erythrocyte transfusion. We tested this by performing standardized neonatal template bleeding times on 20 VLBW infants, during their first week of life, before, and again following a clinically ordered erythrocyte transfusion.
METHODS

Selection of Patients
Patients were eligible for study if they weighed <1500 g at the time of birth, were 7 days old, and were scheduled to receive a packed erythrocyte transfusion (15 ml/kg), by order of their attending
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neonatologist. They were ineligible if they had a platelet count <100Â10 3 /l or had clinical or laboratory evidence of a disorder that would predispose them to abnormal bleeding (i.e., DIC, liver failure). As part of routine clinical care, patients <1000 g at birth were given indomethacin, 0.1 mg/kg per day for 5 days, as prophylaxis for intraventricular hemorrhage (IVH). Patients !1000 g only received indomethacin in an attempt to close a patent ductus arteriosus, and they received three doses of 0.2 mg/kg. All patients had a cranial ultrasound examination at about 7 days of age. The study was approved by the Institutional Review Boards of the University of Florida and the San Diego Children's Hospital, and parents of all enrolled patients signed an informed consent document.
Template Bleeding Times A template bleeding time was performed using the Surgicutt Newborn device (International Technidyne Corporation, Edison, NJ) during the 6-hour period before and again during the 6-hour period following an erythrocyte transfusion. The method for performing the procedure has been reported in detail by Andrew et al., 11 and its sensitivity and reproducibility in neonates has been documented. Briefly, a blood pressure cuff appropriate for the infant's size was placed on the upper extremity and set at a pressure of 20 mm Hg in infants weighing less than 1 kg, and 25 mm Hg in infants weighing 1 to 1.5 kg. The volar surface of the forearm was cleansed with betadine, wiped with alcohol, and allowed to dry. The standard incision (2.5 mm in length and 0.5 mm in depth) was made on the cleansed skin, after which blood was absorbed from the incision, using filter paper, every 15 seconds until the bleeding stopped. A stopwatch, started at the time of the incision, was stopped as soon as the bleeding stopped, and the time interval was recorded as the ''bleeding time.'' We decided prospectively that for any patient on whom the bleeding time exceeded 10 minutes we would stop the test and apply a small bandage.
Hematocrits and Platelet Counts
Complete blood cell counts, including platelet counts, were obtained on venous or arterial blood within a 6-hour period before and again within a 6-hour period after the erythrocyte transfusions. The same source (arterial or venous) was used for each of the paired counts.
Statistical Considerations
Descriptive statistics are given by the mean±SD. An ANCOVA model was fit using normal-based maximum likelihood methods to account for right-censoring at the 10-minute bleeding time for some subjects. The factors considered were birth weight, gestational age, indomethacin treatment (yes or no), and hematocrit, while blocking to account for the paired subject observations. All analyses were carried out using SAS software version 6.12. P values less than <0.05 were considered statistically significant.
RESULTS
Six patients weighed 500 to 750 g, 7 weighed 751 to 1000 g, and 7 weighed 1001 to 1500 g. Thirteen were receiving indomethacin at the time of the study; 12 were extremely low birth weight (ELBW) infants ( <1000 g birth weight) and 1 was being treated for a patent ductus arteriosus. Among the entire group of 20, hematocrits ranged from 0.22 to 0.34 l/l before the transfusions and from 0.31 to 0.44 l/l after. Between the time of the pretransfusion bleeding time and the posttransfusion bleeding time the hematocrits increased by 0.083±0.061 l/l, and platelet counts decreased by 47.3±14.4Â10 3 / l. No changes in leukocyte or neutrophil concentrations were observed.
Three members of our group performed the bleeding times. In 16 of the 20 patients, the pre-and posttransfusion bleeding times were performed by the same investigator. This person knew the hematocrit before the transfusion, but was not aware of the posttransfusion hematocrit at the time of the second bleeding time. All 20 patients tolerated the procedures with no obvious distress, displaying either no reaction or a grimace when the template device was activated. Subjects receiving indomethacin had a bleeding time 135±55 seconds longer than those not receiving indomethacin (p=0.015). This was the case before as well as after transfusion. The posttransfusion bleeding time of the infants not receiving indomethacin was 159±15 seconds.
The hematocrit, over the entire range of hematocrits observed, did not correlate with the bleeding time. However (Figure 1 ) a threshold effect appeared around 0.28 l/l. Patients with a pretransfusion hematocrit 0.28 l/l (n=10) had a reduction of 164±25 seconds in bleeding time following transfusion (p<0.0001). Patients with a pretransfusion hematocrit >0.28 l/l (n=10) had an insignificant reduction in bleeding time following transfusion (28±24 seconds; p<0.0001 vs. those with a pretransfusion hematocrit 0.28 l/l). This difference between groups could not be explained by intergroup differences in the amount of blood transfused or the magnitude of fall in platelet count. Hematocrits increased by a slightly greater margin after transfusion among those with a pretransfusion hematocrit of 0.28 l/l ( Table 1) .
The blood loss from each bleeding time (as a gross estimate by filter paper weight) ranged from 0.2 to 2.0 ml (mean 0.3 ml). No evidence of the template incision remained, in any subject, 7 to 10 days after the procedure. Three of the 20 neonates had a grade 3 IVH (none had a grade 4), and these three were all receiving indomethacin. Two of these had bleeding times !10 minutes, and two had pretransfusion hematocrits less than 0.24 l/l.
DISCUSSION
Intracranial hemorrhage is a leading cause of life-long morbidity among VLBW infants. These hemorrhages almost always occur during the first week of life, a time when anemia due to phlebotomy is common. 12 A prolonged bleeding time on the basis of anemia was first reported by Duke, 13 who also observed that the abnormal bleeding was reversed by blood transfusions. Subsequently, multiple studies in adult animals and adult humans have confirmed that a low hematocrit results in a prolonged bleeding time. 3 -5 However, the effect of hematocrit on bleeding time of VLBW infants, during their first week of life, has not previously been reported.
The accuracy and reproducibility of the bleeding time test is a concern, but the development of standardized techniques and devices has significantly reduced this problem. Andrew et al. 11 performed bleeding times on healthy term and sick term and preterm neonates, using the same device we used in the present study. She reported that 31 healthy term neonates had bleeding times of 80±5 seconds, with an upper limit of 135 seconds, and that this device, which uses the smallest incision of any available, was more sensitive and reproducible than other methods tested in neonates. The same device has subsequently been used to evaluate the effect of inhaled nitric oxide on the bleeding time of neonates.
14 In a group of 20 VLBW infants during the first 7 days of life, we observed that bleeding times were longer, even after transfusion, than Andrew et al. 11 reported in healthy term neonates. In fact, the mean posttransfusion bleeding times, among those not receiving indomethacin, were almost twice as long as Andrew reported. The causes for this discrepancy probably involve differences in the gestational ages of the infants studied, and effects of illness and medications used in our VLBW infants. The independent effects of birth weight and gestational age on the bleeding time could not be evaluated in the present study because of the routine use of indomethacin in ELBW infants. As reported by Andrew et al. 15 and Corazza et al. 16 indomethacin prolonged the bleeding time. Consistent with our hypothesis, in neonates with pretransfusion hematocrits 0.28 l/l, bleeding times decreased after transfusions by an average of over 2-1/2 minutes. In contrast, the effect of the transfusion on the bleeding time was minimal in neonates with a pretransfusion hematocrit >0.28 l/l, suggesting that the hematocrit lengthens the bleeding time only if it is below a threshold. In our study, the threshold of 0.28 l/l was not established a priori, but rather became evident after the data was analyzed. A similar ''threshold effect'' has been observed in adults, on whom clear improvements in the bleeding time and the bleeding tendency are observed after correcting the hematocrit to a value of approximately 0.30 l/l, but little further improvement is achieved with higher hematocrits. 17 Although no attempts were made to correct for differences in the baseline clinical status of the two groups, we did incorporate into the analysis all of those factors thought to directly affect the bleeding time (such as birth weight, gestational age, platelet counts, and medications with known effects on platelet activity).
It is not known whether a 2-1/2-minute prolongation in bleeding time, as the result of a low hematocrit, increases the risk of hemorrhage. In fact, no clear relationship can be established between the prolonged bleeding time and the development of IVH in the three neonates in our study who developed severe IVH. However, clinicians caring for VLBW neonates, and making decisions regarding erythrocyte transfusions for these patients, have not previously been aware of the relationship between low hematocrit and prolonged bleeding time. Certainly, more study is needed to assess the benefits and risks of permitting hematocrits to fall below 0.28 l/l in VLBW infants during their first week of life, and to refine the indications for erythrocyte transfusions in these patients.
